Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain

References

• Cordido F, García Arnés JA, Marazuela Aspiroz M, Torres Vela E; grupo de Neuroendocrinología de la Sociedad Española de Endocrinología y Nutrición. Practical guidelines for diagnosis and treatment of acromegaly. Grupo de Neuroendocrinología de la Sociedad Española de Endocrinología y Nutrición. Endocrinol Nutr. 2013;60(8):457.e1–457.e15.
   PubMedGoogle Scholar
• Somavert 10 mg polvo y disolvente para solución inyectable. Ficha técnica o Resumen de las características del producto. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000409/WC500054629.pdf. Accessed 328, 2017.
   Google Scholar
• Signifor 40 mg, 1 vial polvo +1 jeringa disolvente para solución inyectable. Ficha técnica o Resumen de las características del producto. Available from: https://botplusweb.portalfarma.com/Documentos/2016/12/13/105330.pdf. Accessed 328, 2017.
   Google Scholar
• Pivonello R, Auriemma RS, Grasso LF, et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary. 2017;20:46–62. doi:10.1007/s11102-017-0797-728224405
   PubMed Web of Science ®Google Scholar
• Ferraù F, Albani A, Ciresi A, Giordano C, Cannavò S. Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Front Endocrinol (Lausanne). 2018;6(9):358. doi:10.3389/fendo.2018.00358
   Web of Science ®Google Scholar
• Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94:1500–1508. doi:10.1210/jc.2008-233219208728
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, T B, et al; Pasireotide C2402 Study Group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2;2014:875–884. doi:10.1016/S2213-8587(14)70169-X25260838
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al; Pasireotide C2305 Study Group. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 99;2014:791–799. doi:10.1210/jc.2013-248024423324
   PubMed Web of Science ®Google Scholar
• Schmid HA, Brue T, Colao A, et al. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine. 2016;53:210–219. doi:10.1007/s12020-016-0895-826906713
   PubMed Web of Science ®Google Scholar
• Sheppard M, Bronstein MD, Freda P, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary. 2015;18:385–394. doi:10.1007/s11102-014-0585-625103549
   PubMed Web of Science ®Google Scholar
• Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90:5684–5691. doi:10.1210/jc.2005-033116076947
   PubMed Web of Science ®Google Scholar
• Giustina A, Ambrosio MR, Beck Peccoz P, et al. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest. 2014;37:1017–1030. doi:10.1007/s40618-014-0146-x25245336
   PubMed Web of Science ®Google Scholar
• Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied Methods of Cost-effectiveness Analysis in Health Care. Oxford: Oxford University Press; 2012.
   Google Scholar
• Bernabeu I, Pico A, Venegas E, et al; Spanish ACROSTUDY Group. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary. 19;2016:127–137. doi:10.1007/s11102-015-0691-026553421
   PubMed Web of Science ®Google Scholar
• Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151:439–446.15476442
   PubMed Web of Science ®Google Scholar
• WHO. Qué es la diabetes. Available from: http://www.who.int/diabetes/action_online/basics/es/index1.html. Accessed 328, 2017.
   Google Scholar
• Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York: Oxford University Press; 1994.
   Google Scholar
• Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract. 2015;21:264–274. doi:10.4158/EP14330.OR25370326
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Rusch E, Geer EB; ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine. 2017;55:247–255. doi:10.1007/s12020-016-1182-427896545
   PubMed Web of Science ®Google Scholar
• Baena-Díez JM, Peñafiel J, Subirana I, et al; FRESCO Investigators. Risk of cause-specific death in individuals with diabetes: a competing risks analysis. Diabetes Care. 39;2016:1987–1995. doi:10.2337/dc16-061427493134
   PubMed Web of Science ®Google Scholar
• Schreiber I, Buchfelder M, Droste M, et al; German Pegvisomant Investigators. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007;156:75–82. doi:10.1530/eje.1.0231217218728
   PubMed Web of Science ®Google Scholar
• Cuevas-Ramos D, Fleseriu M. Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther. 2016;10:227–239. doi:10.2147/DDDT.S77999
   PubMed Web of Science ®Google Scholar
• Roset M, Merino-Montero S, Luque-Ramírez M, et al; Spanish group of the OASIS study. Cost of clinical management of acromegaly in Spain. Clin Drug Investig. 32;2012:235–245. doi:10.2165/11599680-000000000-00000
   PubMed Web of Science ®Google Scholar
• Hidalgo A, Oliva J, Rubio M, Zozaya N, Villoro R, García S. Estudios de coste de la diabetes tipo 2: una revisión de la literatura. Madrid: Agencia de Evaluación de Tecnologías Sanitarias - Instituto de Salud Carlos III, Febrero de; 2015.
   Google Scholar
• Nuño-Solinís R, Alonso-Morán E, Arteagoitis JM, Ezkurra P, Orueta JF, Gaztambide S. Costes sanitarios de la población con diabetes mellitus tipo 2 en el País Vasco (España). Endocrinolo Nutric. 2016;63:543–550. doi:10.1016/j.endonu.2016.08.003
   PubMedGoogle Scholar
• Listado de medicamentos afectados por las deducciones del real Decreto-Ley 8/2010 - Agosto 2018. Available from: https://www.mscbs.gob.es/profesionales/farmacia/pdf/DeduccionesAgosto2018.pdf. Accessed 81, 2018.
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. 2014;17:81–89. doi:10.1007/s11102-013-0471-723446424
   PubMed Web of Science ®Google Scholar
• Dreval AV, Trigolosova IV, Misnikova IV, et al. Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect. 2014;3:93–98. doi:10.1530/EC-14-002124692509
   PubMedGoogle Scholar
• Schmid HA, Brueggen J. Effects of somatostatin analogues on glucose homeostasis in rats. J Endocrinol. 2012;212:49–60. doi:10.1530/JOE-11-022421987782
   PubMed Web of Science ®Google Scholar
• Droste M, Domberg J, Buchfelder M, et al. Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur J Endocrinol. 2014;171:59–68. doi:10.1530/EJE-13-043824913198
   PubMed Web of Science ®Google Scholar
• Katznelson L, Laws ER Jr, Melmed S, et al; Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–3951. doi:10.1210/jc.2014-270025356808
   PubMed Web of Science ®Google Scholar
• Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994;41:95–102.8050136
   PubMed Web of Science ®Google Scholar
• Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2000;85:193–199. doi:10.1210/jcem.85.1.631810634386
   PubMed Web of Science ®Google Scholar
• Rubio-Terrés C, Sacristán JA, Badía X, Cobo E, Alonso FG; por el Grupo ECOMED. Métodos utilizados para realizar evaluaciones económicas de intervenciones sanitarias. Med Clín (Barc). 2004;122:578–583. (b).
   Google Scholar
• Leonart LP, Borba HHL, Ferreira VL, Riveros BS, Pontarolo R. Cost-effectiveness of acromegaly treatments: a systematic review. Pituitary. 2018;21:642–652. doi:10.1007/s11102-018-0908-030159696
   PubMed Web of Science ®Google Scholar
• Orlewska E, Stępień R, Orlewska K. Cost-effectiveness of somatostatin analogues in the treatment of acromegaly. Expert Rev Pharmacoecon Outcomes Res. 2018;3:1–11.
   Google Scholar